Nature Cancer November issue cover.

Series on Cancer Immunotherapy

Check out our Series on Cancer immunotherapy for Reviews, Perspectives and opinion pieces on the latest advances and challenges in clinical translation of promising discoveries in this field. 


  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

  • Nature Cancer Series Cover - image of medications in ingestible and injectable form.

    Nature Cancer presents a Series of commissioned Review and Perspective articles highlighting emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical findings into clinical benefit, accompanied by a collection of relevant primary research and News and Comment articles published by Nature Cancer.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


    • Persistent senescent cancer cells have tumor-promoting potential, making their selective elimination a prime therapeutic objective. The death receptor inhibitor cFLIP has now been shown to counter the susceptibility of senescent cells to DR5-mediated extrinsic apoptosis, which can be therapeutically exploited.

      • Dorothy N. Y. Fan
      • Clemens A. Schmitt
      News & Views
    • Combinations of immune-checkpoint blockade and radiotherapy to modulate antitumor immunity have mainly focused on manipulating T cells. A study now shows that combining radiotherapy with activation of macrophages yields potent, abscopal effects in mouse tumor models that may be ready for translation into early clinical trials.

      • Christopher A. Barker
      • Nadeem Riaz
      News & Views
    • Pancreatic ductal carcinoma exists within a heterogenous and complex microenvironment that imposes austere conditions with limited nutrient availability. Clonally separable neoplastic cell populations are now shown to segregate into two distinct metabolic configurations, facilitating symbiotic intratumoral crosstalk to support survival and growth.

      • Dylan Gerard Ryan
      • Christian Frezza
      News & Views
    • Immunovirotherapy is a promising therapeutic strategy for glioblastoma (GBM), a deadly tumor for which effective treatments remain a clinical need. A new study describes an oncolytic herpes simplex virus (oHSV) armed with a bispecific anti-EGFR–CCL5 fusion protein that activates innate and adaptive antitumor immune responses that are highly efficacious in preclinical GBM models.

      • Judit Sanchez Gil
      • Samuel D. Rabkin
      News & Views
    • Intratumoral activation of the complement cascade may have therapeutic potential in patients with lung cancer with strong EGFR signaling, shows a new study. EGFR-triggered expression of CD55 and CD59 prevents opsonization of tumor cells, inhibits antitumor immunity and confers resistance to immune-checkpoint inhibitors.

      • Lubka T. Roumenina
      • Isabelle Cremer
      News & Views
  • As the UK’s feud with the EU over their post-Brexit trade agreement continues, science must not become collateral damage.

  • The Biden administration’s cancer-focused initiatives were reinvigorated this year with the relaunch of the Cancer Moonshot and with ARPA-H plans taking shape. But after a bumpy year of leadership turnover and missteps in funding proposals, how these efforts will play out remains to be seen.

  • Deeper insights into context-specific cancer cell states and the mechanisms that underlie the phenotypic plasticity of different cancer types are key to tackling tumor formation, therapy resistance and recurrence after therapy.

  • Malignant pleural mesothelioma is a challenging disease with few approved treatments. Rapidly expanding insights into the pathogenesis of this cancer and clinical trials are now suggesting a variety of targeted and immune-oncology agents with the potential to address unmet clinical needs.

    • Dean A. Fennell
    • Aleksandra Bzura
    Clinical Outlook
  • The true impact of a paper, a researcher’s work or a journal’s value cannot be captured by any one metric but requires a more nuanced approach that combines quantitative and qualitative measures.

  • The US Supreme Court’s ruling to overturn Roe v. Wade will affect patients with cancer and cancer care providers across the United States. In this time of uncertainty, it is imperative to protect health rights and evidence-based care.

Image of different types of therapies, including pills and injectables, taken from the March 2021 issue cover of Nature Cancer.

Series on Cancer Therapy

Cancer therapy has advanced significantly in recent years, however, cancer remains a major health problem that requires further discovery and innovation to improve outcomes and quality of life for patients.